A meta-analysis of nine SGLT2 inhibitor trials in HF reported reductions in absolute LV volumes (LVEDV, LVESV) and indexed LV mass, and an increase in mean LVEF of +2% (p=0.003), particularly in HFrEF patients. This evidence concerns the gene SLC5A2 and hydrops fetalis.